The effect of statins on cancer cells—review
Statins [3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase, abbreviated HMGCR) inhibitors], are well-known cholesterol-depleting agents. Since the early 1990s, it has been known that statins could be successfully used in cancer therapy, but the exact mechanism(s) of statin activity remains unclear and is now an extensive focus of investigation. So far, it was proven that there are several mechanisms that are activated by statins in cancer cells; some of them are leading to cell death. Statins exert different effects depending on cell line, statin concentration, duration of exposure of cells to statins, and the type of statin being used. It was shown that statins may inhibit the cell cycle by influence on both expression and activity of proteins involved in cell-cycle progression such as cyclins, cyclin-dependent kinases (CDK), and/or inhibitors of CDK. Also, statins may induce apoptosis by both intrinsic and extrinsic pathways. Statin treatment may lead to changes in molecular pathways dependent on the EGF receptor, mainly via inhibition of isoprenoid synthesis. By inhibition of the synthesis of cholesterol, statins may destabilize the cell membrane. Moreover, statins may change the arrangement of transporter OATP1, the localization of HMGCR, and could induce conformational changes in GLUT proteins. In this review, we have tried to gather and compare most of the recent outcomes of the research in this field. We have also attempted to explain why hydrophilic statins are less effective than hydrophobic statins. Finally, we have gathered results from in vivo experiments, presenting the use of statins in combined therapies and discussed a number of molecular targets that could serve as biomarkers predisposing to statin therapy.
KeywordsStatins Cancer Molecular pathways Membrane rafts
We thank Dr. Walis Jones for reading the manuscript. This work was supported by Wroclaw Research Centre EIT+ within the project “Biotechnologies and advanced medical technologies”—BioMed (POIG.01.01.02-02-003/08).
Conflicts of interest
- 7.Matsuoka T, Miyakoshi S, Tanzawa K, Nakahara K, Hosobuchi M, Serizawa N. Purification and characterization of cytochrome P450sca from Streptomyces carbophilus. ML-236B (compactin) induces P450sca in Streptomyces carbophilus that hydroxylates ML-236B to pravastatin sodium (CS-514), a tissue-selective inhibitor of 3-hydroxy-3-methylglutaril coenzyme A reductase. Eur J Biochem. 1989;184:707–13.CrossRefPubMedGoogle Scholar
- 16.Qi X-F, Zheng L, Lee K-J, Kim D-H, Kim C-S, Cai D-Q, et al. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis. 2013;4:e518. doi: 10.1038/cddis.2013.44.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Denoyelle C, Vasse M, Körner M, Mishal Z, Ganné F, Vannier JP, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001;22(8):1139–48.CrossRefPubMedGoogle Scholar
- 29.Helbig G, Hołowiecki J. Ras signaling pathway as a target for farnesyltransferase inhibitors—a new, promising prospects in the treatment for malignant disorders. Rev Pol Wiad Lek. 2004;57(9–10):462–7.Google Scholar
- 35.Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds FH et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl. Acad. Sci. U.S.A. 1983;80(14):4218–22.Google Scholar
- 36.Fromigué O, Haÿ E, Modrowski D, Bouvet S, Jacquel A, Auberger P, et al. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006;13:1845–56.CrossRefPubMedGoogle Scholar
- 38.Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther. 2011;336(2):496–505.CrossRefPubMedGoogle Scholar
- 41.Sandoval-Usme MC, Umaña-Pérez A, Guerra B, Hernández-Perera O, García-Castellano JM, Fernández-Pérez L, et al. Simvastatin impairs growth hormone-activated signal transducer and activator of transcription (STAT) signaling pathway in UMR-106 osteosarcoma cells. PLoS One. 2014;9(1), e87769. doi: 10.1371/journal.pone.0087769.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Westover EJ, Covey DF, Brockman HL, Brown RE, Pike LJ. Cholesterol depletion results in site-specific increases in epidermal growth factor receptor phosphorylation due to membrane level effects. Studies with cholesterol enantiomers. J Biol Chem. 2003;278:51125–33.CrossRefPubMedPubMedCentralGoogle Scholar
- 74.Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer—a plan to move forward. Clin Cancer Res. 2006;12(12):3661–97.CrossRefPubMedGoogle Scholar